Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
2011
The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding events without a significant reduction in recurrent ischemic events. (Funded by Bristol-Myers Squibb and Pfizer; APPRAISE-2 ClinicalTrials.gov number, NCT00831441.).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
43
References
839
Citations
NaN
KQI